Ammar Al-Zoubi

798 total citations
11 papers, 455 citations indexed

About

Ammar Al-Zoubi is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ammar Al-Zoubi has authored 11 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Ammar Al-Zoubi's work include Multiple Myeloma Research and Treatments (9 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (5 papers). Ammar Al-Zoubi is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (5 papers). Ammar Al-Zoubi collaborates with scholars based in United States and Poland. Ammar Al-Zoubi's co-authors include Andrzej Jakubowiak, Mark Kaminski, Asra Ahmed, Ravi Vij, Daniel R. Couriel, Tara Anderson, Daniel Lebovic, Sundar Jagannath, Keith Stockerl‐Goldstein and Kent A. Griffith and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Ammar Al-Zoubi

10 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ammar Al-Zoubi United States 5 377 370 200 71 48 11 455
Zdeněk Adam Czechia 11 521 1.4× 418 1.1× 313 1.6× 81 1.1× 43 0.9× 30 586
Edvan de Queiroz Crusoé Brazil 8 229 0.6× 233 0.6× 156 0.8× 33 0.5× 21 0.4× 41 353
Evžen Gregora Czechia 11 253 0.7× 218 0.6× 130 0.7× 43 0.6× 22 0.5× 29 301
Edward Kavalerchik United States 6 244 0.6× 188 0.5× 125 0.6× 142 2.0× 16 0.3× 17 358
Tara Anderson United States 6 361 1.0× 330 0.9× 173 0.9× 32 0.5× 16 0.3× 10 406
Chiara Nicci Italy 4 403 1.1× 316 0.9× 188 0.9× 73 1.0× 9 0.2× 4 468
Diane E. Durecki United States 6 320 0.8× 320 0.9× 170 0.8× 42 0.6× 16 0.3× 8 374
Marti McKinley United States 9 427 1.1× 395 1.1× 283 1.4× 35 0.5× 14 0.3× 17 507
Jaclyn Cordero United States 6 209 0.6× 204 0.6× 143 0.7× 133 1.9× 81 1.7× 10 343
Joan Bladé Spain 6 416 1.1× 316 0.9× 238 1.2× 100 1.4× 31 0.6× 12 490

Countries citing papers authored by Ammar Al-Zoubi

Since Specialization
Citations

This map shows the geographic impact of Ammar Al-Zoubi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Al-Zoubi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Al-Zoubi more than expected).

Fields of papers citing papers by Ammar Al-Zoubi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Al-Zoubi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Al-Zoubi. The network helps show where Ammar Al-Zoubi may publish in the future.

Co-authorship network of co-authors of Ammar Al-Zoubi

This figure shows the co-authorship network connecting the top 25 collaborators of Ammar Al-Zoubi. A scholar is included among the top collaborators of Ammar Al-Zoubi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ammar Al-Zoubi. Ammar Al-Zoubi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Smith, Christopher, Sanjay Saint, Raymond S. Price, Ammar Al-Zoubi, & Brian C. Callaghan. (2014). Diagnosing One Letter at a Time. New England Journal of Medicine. 372(1). 67–73. 1 indexed citations
3.
Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 120(9). 1801–1809. 311 indexed citations
4.
Jakubowiak, Andrzej, Dominik Dytfeld, Sundar Jagannath, et al.. (2011). Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood. 118(21). 631–631. 18 indexed citations
5.
Ouillette, Peter, Brian Parkin, Li Ding, et al.. (2010). Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks. Clinical Cancer Research. 16(3). 835–847. 50 indexed citations
6.
Jakubowiak, Andrzej, Tara Kendall, Ammar Al-Zoubi, et al.. (2009). Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology. 27(30). 5015–5022. 57 indexed citations
7.
8.
Jakubowiak, Andrzej, Malathi Hari, Tara Kendall, et al.. (2008). Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar®) Correlates with Response to Therapy. Blood. 112(11). 5176–5176. 2 indexed citations
9.
Jakubowiak, Andrzej, Malathi Hari, Ammar Al-Zoubi, et al.. (2007). Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).. Blood. 110(11). 4796–4796. 1 indexed citations
10.
Jakubowiak, Andrzej, et al.. (2006). A phase II study of combination of bortezomib, liposomal doxorubin, and dexamethasone (VDD) as first line therapy for multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 17504–17504. 2 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zdeněk Adam Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Evžen Gregora Breakdown of academic impact, for papers by Edward Kavalerchik Breakdown of academic impact, for papers by Tara Anderson Breakdown of academic impact, for papers by Chiara Nicci Breakdown of academic impact, for papers by Diane E. Durecki Breakdown of academic impact, for papers by Marti McKinley Breakdown of academic impact, for papers by Jaclyn Cordero Breakdown of academic impact, for papers by Joan Bladé
Rankless by CCL
2026